Introduction
============

*Enterococcus* belongs to the Enterococcaceae family, the members of which are symbiotic bacteria in the human intestine ([@b1-etm-0-0-8447]). *Enterococcus* infections may occur in the urinary tract and in meningitis, diverticulitis, bacteremia and endocarditis infections with high mortality rate of \~61% in Portugal ([@b2-etm-0-0-8447]). *Enterococcus* is used as a probiotic to improve the intestinal environment when treating bacterial diarrhea ([@b3-etm-0-0-8447]). There are two main advantages to *Enterococcus* that make it the most popular edible probiotic in animals and humans: i) In the gastrointestinal (GI) tract, *Enterococcus* competes with pathogens and thus decreases their virulence ([@b2-etm-0-0-8447]); ii) *Enterococcus* resists acid stress and cannot be digested by GI-secreted digestive juice ([@b4-etm-0-0-8447]). *E. faecalis* and *E. faecium* are used as digestive agents for the treatment of diarrhea caused by flatulence and indigestion ([@b2-etm-0-0-8447]). However, these two bacteria are difficult to distinguish morphologically. Species identification and genome characterization of these strains may elucidate therapeutic strategies for bacterial infection and probiotic treatment therapy.

The two bacteria were originally assigned to the *Streptococcus* genus ([@b2-etm-0-0-8447]). In 1984, Schleifer *et al* ([@b5-etm-0-0-8447]) indicated that they belonged to the *Enterococcus* genus via DNA-DNA and DNA-rRNA hybridization. These changes were also confirmed in 'Bergey\'s Manual of Systematic Bacteriology Volume 3: The Firmicutes' in 2009, such that '*Streptococcus faecalis*' was revised to *Enterococcus faecalis*, and '*Streptococcus faecium*' was revised to *E. faecium* ([@b6-etm-0-0-8447]). Due to previous changes in species names, the bacterial standard used by a number of manufacturers is inaccurate, which leads to incorrect or inconsistent identification of bacteria. However, numerous species of Enterococci possess the ability to transfer and carry antibiotic resistance genes ([@b7-etm-0-0-8447]). Therefore, the accurate definition and identification of the different sources of the strains in production is essential, as these issues may affect drug production and safe use.

Full bacteria genome sequencing provides an unprecedented method of investigating the biological processes and evolutionary characteristics of bacteria. Using these data, comparative analyses can be made to identify phylogenetic relationships among species, obtain molecular markers for stains and to investigate drug-resistant genes. To date, 527 *E. faecalis* and 778 *E. faecium* draft genomes have been submitted to GenBank (<http://www.ncbi.nlm.nih.gov/genome>; September 3, 2017). Although *E. faecalis* and *E. faecium* are difficult to distinguish morphologically, different genome structures have been identified between the two species. The gene order of *E. faecium* is also significantly different from that of *E. faecalis* according to complete genome data analysis ([@b8-etm-0-0-8447]). In addition, using competitive DNA hybridization, Shanks *et al* ([@b9-etm-0-0-8447]) demonstrated that a number of cell-surface proteins were different between *E. faecalis* and *E. faecium*, which may assist in developing biomarkers for the identification of these species.

Shin Biofermin S is the most widely used commercial medicine for the treatment of dyspepsia, abdominal distension and diarrhea ([@b10-etm-0-0-8447]). Unfortunately, the ingredients, including the species of strains, are yet to be fully elucidated. The present study isolated the strain from Shin Biofermin S. using the Illumina HiSeq 2000 platform, after which the complete genomes of two *E. faecium* strains were determined and annotated. The phylogenetic relationships between these two strains and their genome characteristics were identified and compared with those of other strains of *E. faecalis* and *E. faecium*. This genomic information may provide a reference genome data set of *E*. *faecium* strains to aid further investigations into the ecological and functional diversity of *E*. *faecium*. In addition, the results of the present study identified the species of the two clinically applied strains, 140623 and SBS-1, which may guide the further production of edible probiotics and the optimization of bacterial species.

Materials and methods
=====================

### Isolation of strains and DNA isolation

Strain 140623 was isolated from the National Institute for Food and Drug Control as a control for the production of Lactasin Tablets, and SBS-1 was isolated from Shin Biofermin S (cat. no. X20000191, Biofermin Pharmaceutical Co., Ltd.; <http://www.biofermin.co.jp/>). The 140623 bacterial powder was added to MRS medium (Tiangen Biotech Co., Ltd.) and cultured for 48 h at 37°C. For the isolation of SBS-1, 1 g Shin Biofermin S Tablet was first diluted in 9 ml 7.5% sodium chloride solution and then cultured using 0.1 ml diluted test solution for 48 h at 37°C in MRS medium. Following culture, genomic DNA was isolated using a Bacterial Genome DNA Extraction kit (Tiangen Biotech Co., Ltd.) according to the manufacturer\'s protocol.

### Biochemical identification of 140623 and SBS-1

The 140623 and SBS-1 strains were identified using tests for the VITEK^®^ 2 GP ID card in the VITEK 2 Compact 30 system (BioMérieux SA; <http://www.biomerieux.com>). The growth and biochemical characteristics of these strains were assessed by the Bacteria Preservation Center from the Institute of Microbiology, Chinese Academy of Sciences (Beijing, China). The DuPont™ RiboPrinter^®^ System (Hygiena, LLC) was used to identify species by ribotyping (DuPont).

### Analysis of fatty acid components by gas chromatography-mass spectrometry (GC-MS)

In this experiment, the *Enterococcus faecium* strain CGMCC1.131, provided by The China General Microbiological Culture Collection Center (Institute of Microbiology; Chinese Academy of Sciences) was used as control. Strains were grown in 100 ml MRS medium at 37°C for 48 h, centrifuged at 3000 × g for 10 min at room temperature and washed three times with deionized water. Collected bacteria were subsequently dried at 60°C for 3 h. The fatty acid components were analyzed using an MS 5975C (Agilent Technologies GmbH). The gas chromatography column was an HP-5MS (30 m × 0.25 mm × 0.25 µm) (Agilent Technologies GmbH). The carrier gas was helium. The warming program was 120°C for 5 min, the temperature was raised to 240°C (6°C/min) and maintained for 10 min. The temperature was then raised to 260°C (10°C/min) and maintained for 2 min. The inlet temperature was 250°C, the split ratio was 10:1, the flow was 1.0 and the injection volume was 1 µl. The mass spectrometry conditions were an ion source with an electron energy of 70 eV, a 3 min solvent delay, an electron multiplier voltage gain factor (=1) mode with a full mass scan range of 35--450 amu and a sampling frequency of 2. Multiple reaction monitoring transitions was used to monitor entire eluate with dwell time of 100 ms. The optimum voltage of the first octupole was performed. To analyze the fatty acid methyl esters, 50 mg of samples or fatty acid standards was dissolved with 2 ml boron trifluoride 14% in methanol solution and sealed by N~2~ (250°C), at a flow rate of 5 l/min and a nebulizer gas pressure of 20 psi, immediately following 10 min of ultrasonic shock. After incubation in a 70°C water bath for 30 min, 2 ml N-hexane was added and mixed. The supernatant was collected and washed with 1 ml N-hexane following filtration with 0.22 µm filter membranes and GC-MS analysis.

### Genome sequencing and assembly

The genomes of 140623 and SBS-1 were sequenced using the Illumina HiSeq 2000 platform (Illumina, Inc.). Genomic DNA (1 µg) from each strain was fragmented randomly and purified by electrophoresis using 1.0% agarose gel (Tiangen Biotech Co., Ltd.). The gel was then visualized by ethidium bromide staining under UV light. The DNA fragments were connected to adaptors and sequenced using the Illumina HiSeq 2000. The raw reads were used for *de novo* assembly by SOAPdenovo software (version 2.04; <http://soap.genomics.org.cn/soapdenovo.html>) ([@b11-etm-0-0-8447]). The *de novo* assembly was assessed by kmer and GC depth analysis. Kmer was calculated using Meryl (<https://github.com/marbl/meryl>) with parameter set to kmer=15. SOAP2 reads was used to map the genome and calculate GC depth ([@b11-etm-0-0-8447]). *E. faecium* T110 strain was used as control for the comparison of sequences.

### Genome annotation

The complete genome sequences of 140623 and SBS-1 were annotated using the Basic Local Alignment Search Tool (BLAST, version: 2.2.27) ([@b12-etm-0-0-8447]) against the Gene Ontology (GO) ([@b13-etm-0-0-8447]), Kyoto Encyclopedia of Genes and Genomes (KEGG) ([@b14-etm-0-0-8447]--[@b16-etm-0-0-8447]), Swiss-Prot ([@b17-etm-0-0-8447]), non-redundant database and Clusters of Orthologous Groups (COG) ([@b18-etm-0-0-8447],[@b19-etm-0-0-8447]) databases (Expect (E) Value =1×10^−100,000^). The colinearity analysis of genome was performed by mapping the unigenes with high sequence similarity hits (threshold value=1×10^−30^) ([@b20-etm-0-0-8447]). The pathogenicity and drug resistance of animal pathogen analyses were determined using type III secretion system (T3SS) prediction, which was performed using EffectiveT3 (version 1.0.1) ([@b21-etm-0-0-8447]), Virulence Factors Database (version 20130128) ([@b22-etm-0-0-8447]) and Antibiotic Resistance Genes Database (version 1.1) ([@b23-etm-0-0-8447]) database annotations. Repeated sequence analyses, including small satellite sequences and microsatellite sequences, were performed using Tandem Repeat Finder ([@b24-etm-0-0-8447]). Ribosomal RNA (rRNA) and bacterial small RNA (sRNA) were predicted by searching the Rfam databases (version 10.1) ([@b25-etm-0-0-8447]). The remainder of the potential noncoding RNAs was predicted using RNAmmer (version 1.2) ([@b26-etm-0-0-8447]) and tRNAscan (version: 1.23) ([@b27-etm-0-0-8447]) software. Potential virulence-associated genes were predicted by BLAST queries against the pathogen-host interaction gene database (<http://www.phi-base.org>). Genes of antibiotic resistance were predicted using Antibiotic Resistance Genes Database (ARDB) (<https://ardb.cbcb.umd.edu/>).

Results
=======

### Biochemical identification results of 140623 and SBS-1

Biochemical identification tests revealed that the two tested strains were Gram-positive, spherical bacterium. No spores were observed when culturing the bacteria. The catalase and oxidase tests were negative in both strains. These bacteria could grow in air and were able to survive and multiply at either 10 or 45°C. D-glucose, D-fructose, D-mannose, D-ribose, D-galactose, L-arabinose, lactose, sucrose, maltose, trehalose, melibiose, cellobiose, mannitol, sodium gluconate, esculin, salicin and amygdalin tests were all positive, while the D-xylose, L-xylose, D-arabinose, L-sorbose, L-rhamnose, melezitose, raffinose and sorbitol tests exhibited negative results in the bacteria ([Table I](#tI-etm-0-0-8447){ref-type="table"}). These results indicated that the two strains were *E. faecium*. The RiboPrinter ribotyping results also indicated the two strains demonstrated high similarity with *E. faecium* ([Fig. 1](#f1-etm-0-0-8447){ref-type="fig"}).

### GC-MS analysis of fatty acid components

The two strains revealed a GC-MS result of C14:0, C16:1^Δ9^, C16:0, C18:1^Δ9^ and C18:0 peaks. A specific 2-C8H17-C19:0 peak was observed in the tested strains. The concentrations of C14:0, C16:1^Δ9^, C16:0, C18:1^Δ9^, C18:0 and 2-C8H17-C19:0 were 6.60, 9.61, 17.50, 28.14, 3.93 and 36.29, respectively, in strain 140623. The concentrations of C14:0, C16:1^Δ9^, C16:0, C18:1^Δ9^, C18:0, and 2-C8H17-C19:0 were 6.29, 8.63, 17.58, 30.27, 3.95 and 32.47, respectively, in SBS-1. The two strains had similar ratios of C14:0, C16:1^Δ9^, C16:0, C18:1^Δ9^, C18:0, 2-C8H17-C19:0 (1.0:1.5:2.7:4.3:0.6:5.5 in 140623; 1.0:1.4:2.8:4.8:0.6:5.2 in SBS-1) with the control (1.0:1.4:2.7:4.3:0.5:5.0 in control) *E. faecium* ([Table II](#tII-etm-0-0-8447){ref-type="table"}).

### Genome assembly of 140623 and SBS-1

Illumina HiSeq 2000 generated 2,132 Mb and 2,413 Mb raw data from 140623 and SBS-1, respectively. The sequence data of which are available under NCBI BioProject number PRJNA549093. The *de novo* assembly of 140623 generated 6 scaffolds (N50, 2,713,725 bp) and 63 contigs (N50, 125,144 bp), indicating that the 140623 genome had 2,812,926 bp nucleotides with 38.22% GC content ([Table III](#tIII-etm-0-0-8447){ref-type="table"}). The complete genome of SBS-1 contained 2,797,745 bp nucleotides with 38.25% GC content, which had 10 scaffolds (N50, 2,177,304 bp) and 38 contigs (N50, 208,101 bp; [Table IV](#tIV-etm-0-0-8447){ref-type="table"}).

The genome characteristics, including gene distribution and genome GC content distribution. A higher GC skew (−) value was found in SBS-1, which may due to genome variation between the two strains ([Fig. 2A and B](#f2-etm-0-0-8447){ref-type="fig"}). In the present study, the T110 strain was used as a control to compare the genome sequences between the strains. The collinearity analysis of the two strains and T110 demonstrated that 140623 and SBS-1 were most closely associated with sequences from T110 ([Fig. 2C and D](#f2-etm-0-0-8447){ref-type="fig"}). Similar arrangement of sequences from the 140623 and SBS-1 genomes was found by comparing them with sequences from the T110 genome. The genome collinearity analysis of amino acid and nucleotide sequences exhibited similar arrangements in 140623 and SBS-1 compared with T110 ([Fig. 2C and D](#f2-etm-0-0-8447){ref-type="fig"}).

### Annotation of the 140623 and SBS-1 genomes

Gene annotations identified 2,766 genes (average gene length, 889 bp) and 2,734 genes (average gene length, 893 bp) from 140623 and SBS-1, respectively. Compared with the intergenic region length (140623, 355,200 bp; SBS-1, 356,384 bp), larger gene regions were identified in the 140623 genome (2,457,726 bp) and SBS-1 genome (2,441,361 bp), representing 87.37 and 87.26% of the complete genome sequences, respectively. Higher GC contents in gene regions (140623, 39.07%; SBS-1, 39.09%) were observed when compared with intergenic regions (140623, 32.42%; SBS-1, 32.57%). Both genomes contained 70 tandem repeat sequences (7,954 bp in 140623, 9,079 bp in SBS-1), which accounted for 0.2828 and 0.3245% of the genomes of 140623 and SBS-1, respectively. In 140623, 39 minisatellite DNA sequences, 2 microsatellite DNA sequences, 41 transfer RNAs (tRNAs) and 4 sRNAs were identified. The SBS-1 genome contained 38 minisatellite DNA sequences, 1 microsatellite DNA sequence, 3 rRNAs, 54 tRNAs and 4 sRNAs ([Table IV](#tIV-etm-0-0-8447){ref-type="table"}).

The distribution of GO categories was similar between the 140623 and SBS-1 genomes. In 140623 and SBS-1, the genes associated with 'catalytic activity', 'metabolic process', 'cellular process' and 'binding' were abundant ([Fig. 3](#f3-etm-0-0-8447){ref-type="fig"}). The core genes were primarily involved in the following KEGG categories: 'Environmental Information Processing-Membrane Transport' (478 genes in 140623 and 474 genes in SBS-1) and 'Metabolism-Carbohydrate Metabolism' (360 genes in 140623 and 350 genes in SBS-1; [Fig. 4](#f4-etm-0-0-8447){ref-type="fig"}). According to the COG classification, 1,745 genes in 140623 and 1,730 genes in SBS-1 were included. In the categories other than 'Carbohydrate transport and metabolism', 'Translation, ribosomal structure and biogenesis', 'Transcription' and 'Replication, recombination and repair', the two strains had the same gene numbers ([Fig. 5](#f5-etm-0-0-8447){ref-type="fig"}).

### Virulence- and drug resistance-associated genes

A total of 6 putative virulence-associated genes were identified from 140623 and SBS-1 genomes, including AphA, CBL1, CPA1, GyrA, MGG_00383 and SOD2 ([Table SI](#SD1-etm-0-0-8447){ref-type="supplementary-material"}). Analysis using ARDB revealed that there were only a few potential genes of antibiotic resistance (15 genes in both 140623 and SBS-1 genomes; [Table SII](#SD1-etm-0-0-8447){ref-type="supplementary-material"}). The complete sequences of the 140623 and SBS-1 genomes each exhibited 31 genes associated with bacterial toxins according to vfdb annotation ([Table SIII](#SD1-etm-0-0-8447){ref-type="supplementary-material"}).

Discussion
==========

As a popular medicine for probiotic therapy to treat with patients with diarrhea, the safety of Shin Biofermin S is paramount. Therefore, in the present study, the species of the SBS-1 strain isolated from a commercial medicine (Shin Biofermin S) was determined via genome sequencing. Species identification is important for evaluating safety and is favorable for formulating therapeutic strategies. The scientific names of *E. faecium* have been changed several times. *Streptococcus faecalis* and *Streptococcus faecium* were separate until 1984, when DNA-DNA and DNA-rRNA hybridization tests revealed that they belonged to *Enterococcus* instead ([@b5-etm-0-0-8447]). Bergey\'s Manual of Systematic Bacteriology Volume 3: The Firmicutes also demonstrated this result ([@b6-etm-0-0-8447]), such that *Streptococcus faecalis* was renamed *Enterococcus faecalis*. In the food and health industry, *E. faecium* and *E. faecalis* have been used to improve the intestinal environment by regulating its inflammatory status and the gut microflora ([@b2-etm-0-0-8447]). However, the definition of strains is inaccurate among different companies. The bacterial strain is the only active ingredient in probiotics. Thus, if the identity of the original strain species is not assured, its safety cannot be guaranteed. The present study identified two *E. faecium* strains from the National Institute for Food and Drug Control, and Shin Biofermin S. Biochemical identification, gene fingerprinting, fatty acid component analysis and genome sequencing were all used to clarify the species of these two strains.

Growth and sugar component tests classified the two strains into *E. faecium*. The growth of *E. faecium* requires high-quality culture medium, such as agar with human, rabbit or horse blood. This species produced L-arabinose, in line with a previous report ([@b28-etm-0-0-8447]), while *E. faecium* could not generate L-arabinose. In addition, the RiboPrinter automatic microbial genetic fingerprint identification system, which is a tool designed for the identification of bacteria, suggested that the two strains were *E. faecium*. A number of studies have demonstrated that this method is a highly targeted and effective approach to identify different species. Previously, the two strains seemed to be *E. faecalis* ([@b2-etm-0-0-8447],[@b5-etm-0-0-8447]), while the present analyses strongly supports *E. faecium*.

The fatty acid composition of the strains was analyzed in the present study via GC-MS, which also supported the classification of the two strains as *E. faecium*. The characteristic peaks of C14:0, C16:1^Δ9^, C16:0, C18:1^Δ9^, C18:0 and 2-C8H17-C19:0 were similar between the two strains. This result demonstrated the high homology between 140623 and SBS-1. The fatty acid component of these two strains was also similar to previously reported *E. faecium* ([@b29-etm-0-0-8447]).

The genome sizes of the two strains were 2,812,926 (140623) and 2,797,745 (SBS-1) bp. Zhong *et al* ([@b30-etm-0-0-8447]) reported five strains of *E. faecium* genome sizes ranging from 2.64--2.99 Mb. The genome sizes identified in the present study were also in this range. Another report indicated that the genome of an *E. faecium* strain isolated from the bloodstream of a patient in Melbourne, Australia, contained 3 circular plasmids and a 2.9 Mb chromosome ([@b31-etm-0-0-8447]). The chromosome of *E. faecium* TX16 was 2,698,137 bp ([@b8-etm-0-0-8447]). In general, it appears that genome size changes among different strains throughout evolution.

The genomes of 140623 and SBS-1 had 2,766 and 2,734 protein-coding open reading frames (ORFs), respectively. When three *E. faecium* were isolated from bovine feces, it was revealed that they contained 2,719, 2,665 and 2,659 genes, respectively ([@b32-etm-0-0-8447]). In *E. faecium* TX16, 2,703 protein-coding ORFs were identified on the chromosome and the three plasmids contained 43, 85 and 283 ORFs, respectively ([@b8-etm-0-0-8447]). These previous reports indicate that the genomes of *E. faecium* strains from different sources have similar gene counts, indicating evolutionarily conserved and similar functions. Similar gene annotations, such as GO, KEGG and COG analyses, also supported this conclusion.

Virulence- and drug resistance-associated genes in *E. faecium* were limited compared with the results of *E. faecalis*. The present results demonstrated that AphA, CBL1, CPA1, GyrA, MGG_00383 and SOD2 were exhibited by the two strains and may be associated with pathogen-host interaction. CBL1 of *Fusarium graminearum* has been reported to be associated with pathogenicity, indicating a role in host infection ([@b33-etm-0-0-8447]). Waters *et al* ([@b34-etm-0-0-8447]) demonstrated the ciprofloxacin-resistant function of GyrA. The SOD2 gene is associated with the loss of pathogenicity in bacteria ([@b35-etm-0-0-8447]). The present study indicated that the evolution of this species conferred resistance mechanisms in natural environments and industrial environments. These resistance mechanisms provide potential for clinical use in food and drug safety.

The results of the present study indicated that the species of 140623 and SBS-1 was *E. faecium*. The biochemical assays and RiboPrinter ribotyping were comparable, both characterizing the strains as *E. faecium*; GC-MS analysis indicated specific peaks of fatty acid components that were similar to other *E. faecium* strains; genome features of 140623 and SBS-1 demonstrated high conservation of these strains as *E. faecium*, which was also confirmed by phylogenetic analysis.

Taken together, the results of the present study demonstrated that 140623 and SBS-1 from the National Institute for Food and Drug Control and Shin Biofermin S were *E. faecium* rather than *E. faecalis*. These data first elucidated the genome information of SBS-1 strain from Shin Biofermin S, which is a commercial medicine used to treat diarrhea ([@b2-etm-0-0-8447]). The present study demonstrated that the strain is similar with 140623 and that the variations in the SBS-1 strain served potential roles in resistance. The virulence- and drug resistance-associated genes identified in the present study, which participate in antibiotic resistance, should be further investigated. These could serve as key molecular factors for SBS-1 strain security during treatment. In conclusion, the results of the present study may therefore be valuable for distinguishing different species of the *Enterococcus* genus and guiding edible probiotic usage.
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###### 

Biochemical identification of two strains.

  Test items         140623                   SBS-1
  ------------------ ------------------------ ------------------------
  Gram staining      Positive                 Positive
  Cell shape         spherical                spherical
  Spore              −                        −
  Catalase test      −                        −
  Oxidase test       −                        −
  Growth in air      \+                       \+
  Growth at 45°C     \+                       \+
  Growth at 10°C     \+                       \+
  6.5% NaCl growth   \+                       \+
  pH 9.6 growth      \+                       \+
  pH 4.5 growth      −                        −
  D-glucose          \+                       \+
  D-fructose         \+                       \+
  D-mannose          \+                       \+
  D-ribose           \+                       \+
  D-xylose           −                        −
  L-xylose           −                        −
  D-galactose        \+                       \+
  D-arabinose        −                        −
  L-arabinose        \+                       \+
  L-sorbose          −                        −
  L-rhamnose         −                        −
  Lactose            \+                       \+
  Sucrose            \+                       \+
  Maltose            \+                       \+
  Trehalose          \+                       \+
  Melibiose          \+                       \+
  Cellobiose         \+                       \+
  Melezitose         −                        −
  Raffinose          −                        −
  Sorbitol           −                        −
  Mannitol           \+                       \+
  Sodium gluconate   \+                       \+
  Esculin            \+                       \+
  Salicin            \+                       \+
  Amygdalin          \+                       \+
  Species            *Enterococcus faecium*   *Enterococcus faecium*

-, negative result, +, positive result.

###### 

Relative content of standard strains and the strains of lactasin tablets (%).

  Strains          C14:0   C16:1^Δ9^   C16:0   C18:1^Δ9^   C18:0   2-C~8~H~17~- C19:0   Content ratio of component
  ---------------- ------- ----------- ------- ----------- ------- -------------------- ----------------------------
  140623           6.60    9.61        17.50   28.14       3.93    36.29                1.0:1.5:2.7:4.3:0.6:5.5
  SBS-1            6.29    8.63        17.58   30.27       3.95    32.47                1.0:1.4:2.8:4.8:0.6:5.2
  *Enterococcus*   6.68    9.66        17.85   28.56       3.43    33.5                 1.0:1.4:2.7:4.3:0.5:5.0

*faecium* control

###### 

Summary of genome assembly of the two strains.

  A, 140623                           
  -------------------- -------------- ------------
  Total number, n      6              63
  Total length, bp     2,812,926      2,765,223
  N50, bp              2,713,725      125,144
  N90, bp              2,713,725      36,082
  Max length, bp       2,713,725      460,559
  Min length, bp       613            211
  GC content, %        38.22          38.22
                                      
  **B, SBS-1**                        
                                      
  **Characteristic**   **Scaffold**   **Contig**
                                      
  Total number, n      10             38
  Total length, bp     2,797,745      2,754,045
  N50, bp              2,177,304      208,101
  N90, bp              415,863        49,841
  Max length, bp       2,177,304      447,113
  Min length, bp       1,148          232
  GC content, %        38.25          38.25

###### 

Genome component of the two strains.

                                       140623      SBS-1
  ------------------------------------ ----------- -----------
  Genome size, bp                      2,812,926   2,797,745
  GC content, %                        38.23       38.26
  Gene number                          2,766       2,734
  Gene length, bp                      2,457,726   2,441,361
  Gene average length, bp              889         893
  Gene length/genome, %                87.37       87.26
  GC content in gene region, %         39.07       39.09
  Intergenic region length, bp         355,200     356,384
  GC content in intergenic region, %   32.42       32.57
  Intergenic region length/genome, %   12.63       12.74
  Tandem repeat number                 70          70
  Tandem repeat length, bp             7,954       9,079
  Tandem repeat size, bp               5--676      5--692
  Tandem repeat length/genome, %       0.2828      0.3245
  Minisatellite DNA Number             39          38
  Microsatellite DNA number            2           1
  rRNA number                          0           3
  tRNA number                          41          54
  sRNA number                          4           4
  Genomic island number                0           0
  Prophage number                      0           0

rRNA, ribosomal RNA; tRNA, transfer RNA; sRNA, bacterial small RNA.
